Navigation Links
Adalimumab may reduce health-care costs for Crohn's disease patients
Date:11/12/2008

Inflammatory bowel disease (IBD) is a term that refers to both ulcerative colitis (UC) and Crohn's disease (CD). IBD occurs most frequently in people in their late teens and twenties. There have been cases in children as young as two years old and in older adults in their seventies and eighties; men and women have an equal chance of getting the disease.

While the cause(s) of IBD are not known, one theory is based on genetics, indicating that IBD runs in families. About 15 percent to 30 percent of patients with IBD have a relative with the disease. Research is underway to find out if a specific gene or a group of genes makes a person more susceptible to getting the disease. Additionally, many changes in the body's immune system have been discovered in patients with IBD. There is a large amount of research being done in this area as well, including studies to find out if IBD is caused by an infectious agent.

Two recent studies published in Gastroenterology and Clinical Gastroenterology and Hepatology further our understanding of these major illnesses.

Adalimumab Therapy May Provide Important Economic Benefits for Crohn's Disease Patients

Crohn's disease (CD) patients treated with adalimumab have lower one-year risks of hospitalization and surgery, reports a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

Adalimumab is an anti-tumor necrosis factor (TNF) monoclonal antibody, of human origin, effective for inducing and maintaining clinical response and remission in patients with moderate to severe CD. It is approved for the treatment of CD in North America and Europe.

All data used in these analyses were collected during the Crohn's Trial of the Fully Human Antibody Adalimumab for Remission Maintenance (CHARM) trial, a multi-center, Phase III, double-blind, randomized, placebo-controlled study. This analysis was the firs
'/>"/>

Contact: Alissa Cruz
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
2. HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
3. Data Show that Abbotts HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
4. Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies
5. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
6. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
7. Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
8. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
9. Dual treatment for stroke leads to improved recovery rates, reduced mortality
10. Calcium plus vitamin D supplementation is not associated with a reduced breast cancer risk
11. Study: Smoking Ban Would Help Reduce Heart Attack Admissions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 Paradigm Physical Therapy is ... new therapeutic treatment for their patients. Dry needling is ... a variety of musculoskeletal problems. , In this invasive ... into the skin and muscle to create a trigger ... the needle helps to deactivate and release the trigger ...
(Date:9/16/2014)... Wearable electronic activity monitors hold great promise in ... goals. These increasingly sophisticated devices help the wearers ... and bodily responses. This information is organized into ... Given the large and quickly growing market for ... Medical Branch at Galveston analyzed 13 of these ...
(Date:9/16/2014)... DC September 14, 2014 A ... everolimus-eluting stents (EES) and drug-eluting balloons (DEB) ... stents found that EES provided superior late ... , Findings were reported today at ... scientific symposium. Sponsored by the Cardiovascular Research ...
(Date:9/16/2014)... September 16, 2014 Seven heroes who ... world will be honored in New York City on ... ), the only global recognition and funding program that ... by the media as the “Nobel Prize for Child ... created life-changing programs that benefit children in countries around ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. ... the first objective scientific way to diagnose major depression in ... levels of nine genetic indicators (known as "RNA markers") in ... respond to cognitive behavioral therapy, one of the most common ... therapy worked, Northwestern University researchers report. Depression affects nearly ...
Breaking Medicine News(10 mins):Health News:Paradigm Physical Therapy Introduces Dry Needling 2Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3
... ... not friendly one-on-one conversation. , ... New York, NY (PRWEB) November 18, 2009 -- A new national ... e-patients to “friend” them on Facebook. Instead, health organizations would be better off ...
... Young football ... sustain a series of even small head bumps may be at increased risk of long-term brain ... Boston (Vocus) November 19, 2009 ... But players who sustain a series of even small head bumps may be at increased risk ...
... Plavix bested by latest anti-clotting alternatives , WEDNESDAY, Nov. ... three new trials suggest that the latest generation of ... clopidogrel (Plavix). , In one study, dabigatran etexilate (marketed ... is not yet approved in the United States) proved ...
... Preliminary report from the Harvard School of Public Health reveals students ... Think your kids won,t eat healthy foods? Think again. A preliminary ... of Public Health, funded by Project Bread, proves that kids not ... healthy foods than they would if they were eating a traditional ...
... Calif., Nov. 18 Endologix, Inc. (Nasdaq: ... aortic disorders, announced today that it has received ... United States Food and Drug Administration ("FDA") to ... a bilateral percutaneous approach to endovascular abdominal aortic ...
... announces the November 2009 publication of a special ... devoted to residential design for persons with neurodisability. ... of the long-term living environment can improve quality ... who are cognitively, behaviorally and/or physically challenged due ...
Cached Medicine News:Health News:Older E-Patients Prefer Facts, Not Friendship from Health Organizations Communicating Via Social Media, According to Path of the Blue Eye Project Survey 2Health News:Throw a Yellow Flag on Football-related Head Injuries, Warns the Harvard Mental Health Letter 2Health News:Newer Blood Thinners May Outperform Old Standbys 2Health News:Newer Blood Thinners May Outperform Old Standbys 3Health News:New Study Proves Kids Like Eating Healthy Food 2Health News:New Study Proves Kids Like Eating Healthy Food 3Health News:Endologix Receives IDE Approval for Fully Percutaneous Approach to EVAR 2Health News:Endologix Receives IDE Approval for Fully Percutaneous Approach to EVAR 3Health News:Residential design for persons with neurological disability 2Health News:Residential design for persons with neurological disability 3
(Date:9/16/2014)... 2014 Research and Markets ... Laparoscopy Devices Industry Report 2014" report to ... Devices Industry Report 2014 is a professional and ... global laparoscopic devices. The report provides ... classifications, applications and industry chain structure. The laparoscopic ...
(Date:9/16/2014)... 2014   Vestagen Technical Textiles, Inc. today ... hospitals. The myComfort™ line of patient apparel is protected ... is fluid repellant, breathable and in studies done in ... bacteria on the fabric i . "It,s ... chain of transmission. We want myComfort to be a ...
(Date:9/16/2014)... CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... and restatement of its outstanding Series C-2, C-3, ... as well as the warrants issued in its ... remove anti-dilution, price reset and certain change of ...
Breaking Medicine Technology:Global Laparoscopy Devices Industry Report 2014 2New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
... Multichannel, with it's streamlined design, ... routine laboratory tasks. The multichannel ... Soft-touch tip ejection, Super blow-out ... models), Entire pipette autoclavable, streamlined ...
... wide variety of applications. • Whole pipette is ... freely rotated against the handle to work in ... angle towards the microtiter plate. • The special ... common pipette tips, and provides a firm, parallel ...
... with 96-well plates in mind, Pipetman ... molecular biology applications: PCR* sequencing, immunology ... etc. Used with Diamond Tips from ... product will maximize performance and assure ...
... Multichannel, with it's streamlined design, ... routine laboratory tasks. The multichannel ... Soft-touch tip ejection, Super blow-out ... models), Entire pipette autoclavable, streamlined ...
Medicine Products: